Business Context and Reporting Period
This Form 8-K filing by Syndax Pharmaceuticals Inc. (SNDX) reports a corporate governance update. The report date is December 18, 2025, covering events occurring on that same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on amendments to the company's Bylaws and does not contain financial performance data.
Material Changes
On December 18, 2025, the Board of Directors approved amendments to the Amended and Restated Bylaws. The primary change is that, effective immediately, shares of the Company's capital stock shall be issued solely in uncertificated form. Existing certificates issued prior to this date remain valid in certificated form until surrendered to the Company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is a procedural notice regarding the transition to uncertificated stock.
Investor Verification Checklist
- Confirm the effective date of the uncertificated stock issuance (December 18, 2025).
- Review the full text of the Amended and Restated Bylaws filed as Exhibit 3.1 for complete legal details.
- Verify procedures for shareholders holding physical certificates issued prior to the amendment date.